Related Experiment Video
Updated: Mar 21, 2026
12:38
Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
Published on: November 6, 2021
3.2K
A High-Adhesive Lysine-Cyclic RGD Peptide Designed for Selective Cell Retention Technology
Keyu Luo1,2,3, Tieniu Mei1,2,3, Zhiqiang Li1,2,3
11 Department of Orthopedics, Southwest Hospital, National & Regional United Engineering Laboratory of Tissue Engineering, The Third Military Medical University , Chongqing, China .
Tissue Engineering. Part C, Methods
|May 8, 2016
Summary
A novel lysine-cyclic RGD peptide enhances demineralized bone matrix (DBM) for selective cell retention (SCR) bone grafting. This DBM/LcRGD composite improves osteoprogenitor cell adhesion and bone regeneration in vivo.
Area of Science:
- Biomaterials Science
- Tissue Engineering
- Regenerative Medicine
Background:
- Cell adhesion is crucial for biomaterials in selective cell retention (SCR) technology for rapid bone graft fabrication.
- Demineralized bone matrix (DBM) has limitations in cell adhesion and osteoinduction due to processing.
- Enhancing DBM's properties is key to improving SCR technology for bone regeneration.
Purpose of the Study:
- To design a lysine-cyclic RGD (LcRGD) peptide to improve cell adhesion on scaffolds.
- To modify demineralized bone matrix (DBM) with LcRGD peptide to create a DBM/LcRGD composite.
- To evaluate the enhanced cell adhesion, osteoinduction, and osteogenic capacity of the DBM/LcRGD composite for bone grafting.
Main Methods:
- Synthesized a lysine-cyclic RGD (LcRGD) peptide incorporating positively charged amino acids and the RGD sequence.
- Modified demineralized bone matrix (DBM) with the LcRGD peptide to create a DBM/LcRGD composite.
- Assessed cell adhesion of human bone marrow-derived mesenchymal stem cells and osteoprogenitor retention.
- Evaluated osteoinduction in vitro and osteogenic capacity in vivo.
Main Results:
- The DBM/LcRGD composite demonstrated significantly enhanced adhesion performance for mesenchymal stem cells.
- The composite effectively retained more osteoprogenitors from bone marrow compared to unmodified materials.
- DBM/LcRGD exhibited superior osteoinduction in vitro and enhanced osteogenic capacity in vivo.
Conclusions:
- LcRGD peptide serves as an effective modifier for DBM in SCR technology.
- The DBM/LcRGD composite shows promise for improving bone transplantation and regeneration.
- This approach enhances biomaterial performance for clinical bone grafting applications.
